Effects of Pien Tze Huang on angiogenesis in vivo and in vitro

Chinese Journal of Integrative Medicine

Volumn 18, Issue 6, 2012, Pages 431-436

  Shen, A Ling ^a   Hong, Fei ^b   Liu, Li Ya ^a   Lin, Jiu Mao ^a   Zhuang, Qun Chuan ^a   Hong, Zhen Feng ^a   Peng, Jun ^a,b  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Zhangzhou Pien Tze Huang Pharmaceutical Co Ltd   (China)

Author keywords

Chinese medicine; Multi target agents; Pien Tze Huang; Tumor angiogenesis

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANGIOGENESIS INHIBITOR; CHINESE DRUG; FIBROBLAST GROWTH FACTOR 2; HERBACEOUS AGENT; MESSENGER RNA; PIEN TZE HUANG; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CAPILLARY TUBE; CELL DENSITY; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHINESE MEDICINE; CHORIOALLANTOIS; COLON ADENOCARCINOMA; CONTROLLED STUDY; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; WOUND HEALING;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DRUGS, CHINESE HERBAL; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION; HT29 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864690330     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-012-1121-z     Document Type: Article

References (30)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
2. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial award lecture. Cancer Res 1986;46:467-473.
3. Folkman J, Shing Y. Angiogenesis . J Biol Chem 1992;267:10931-10934.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995;1:27-31.
5. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
6. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-3051.
7. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010;60:222-243.
8. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
9. Breier G, Risau W. The role of vascular endothelial growth factor in blood vessel formation. Trends Cell Biol 1996;6:454-456.
10. Stromblad S, Cheresh DA. Integrins, angiogenesis and vascular cell survival. Chem Biol 1996;3:881-885.
11. Risau W. Mechanisms of an giogenesis . Nature 1997;386:671-674.
12. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002;29:3-9.
13. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10-14.
14. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
15. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001;276:3222-3230.
16. Vlodavsky CR, Bråkenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of "PDGFBB and FGF-2". Nat Med 2003;9:604-613.
17. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-178.
18. Eikesdal HP, Kalluri R. Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol 2009;19:310-317.
19. Muñoz-Chápuli R, Quesada AR, Angel Medina M. Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci 2004;61:2224-2243.
20. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009;27:4865-4873.
21. Higa GM, Abraham J. Biological mechanisms of bevacizumabassociated adverse events. Expert Rev Anticancer Ther 2009;9:999-1007.
22. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465-477.
23. Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol 2007;9:767-776.
24. Ji HF, Li XJ, Zhang HY. Natural products and drug discovery. EMBO Reports 2009;10:194-200.
25. Zhao J, Jiang P, Zhang WD. Molecular networks for the study of TCM pharmacology. Brief Bioinform 2009;11:417-430.
26. Lin JM, Chen YQ, Wei LH, Chen XZ, Xu W, Hong ZF, et al. Hedyotis Diffusa Willd extract induces apoptosis via activation of the mitochondrion-dependent pathway in human colon carcinoma cells. Int J Oncol 2010;37:1331-1338.
27. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China. Beijing: Chinese Medical Science and Technology Press; 2010:573-575.
28. Xu YY, Yu EX. Clinical analysis of the effect of Pien Tze Huang in treatment of 42 patients with moderate or advanced liver cancer. Shanghai J Tradit Chin Med (Chin) 1994;12:4-5.
29. Gu ZX. Therapeutical observation of advanced colon cancer. Chin Tradit Patent Med (Chin) 1993;15:23.
30. Lin JM, Wei LH, Chen YQ, Liu XX, Hong ZF, Sferra TJ, et al. Pien Tze Huang-induced apoptosis in human colon cancer HT-29 cells is associated with regulation of the Bcl-2 family and activation of caspase 3. Chin J Integr Med 2011;17:685-690.